A Phase II/III drug registration trial of NTI-164
Latest Information Update: 15 Oct 2024
Price :
$35 *
At a glance
- Drugs NTI 164 (Primary)
- Indications Pervasive child development disorders
- Focus Registrational; Therapeutic Use
- Sponsors Neurotech International
- 15 Oct 2024 New trial record